Literature DB >> 12750291

Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer.

J Timothy Posey1, Mark S Soloway, Sinan Ekici, Mario Sofer, Francisco Civantos, Robert C Duncan, Vinata B Lokeshwar.   

Abstract

Despite the development of nomograms designed to evaluate the prognosis of a patient with prostate cancer (CaP), the information has been limited to prostate-specific antigen (PSA), clinical stage, Gleason score, and tumor volume estimates. To improve our ability to predict prognosis, information regarding the molecular properties of CaP is needed. Hyaluronic acid (HA) is a glycosaminoglycan that promotes tumor metastasis. Hyaluronidase (HAase) is an enzyme that degrades HA into angiogenic fragments. We recently showed that in CaP tissues, whereas HA is localized mostly in the tumor-associated stroma, HYAL1 type HAase is exclusively localized in CaP cells (Lokeshwar et al. J. Biol. Chem., 276: 11922-11932, 2001). We evaluated the prognostic potential of HA and HYAL1 in CaP by immunohistochemistry. Archival CaP specimens were obtained from patients who underwent radical retropubic prostatectomy for clinically localized CaP. Group 1 (n = 25) included patients who showed biochemical recurrence (PSA >0.4 ng/ml; mean recurrence: 21.3 months). Group 2 included patients with no clinical or biochemical recurrence (n = 45; mean follow-up: 80.9 months). For HA and HYAL1 staining, a biotinylated HA-binding protein and an anti-HYAL1 antibody were used. The staining was evaluated on the basis of intensity (0 to 3+) and as dense or sparse (for HA staining only) and then grouped as low grade and high grade. In CaP specimens, HYAL1 was exclusively expressed in tumor cells. Although the stroma was stained positive for HA, 40% of tumor cells also expressed HA. HA, HYAL1, and combined HA-HYAL1 staining predicted progression with 96%, 84%, and 88% sensitivity, 55.5%, 80%, and 84.4% specificity, and 70%, 81.4%, and 85.7% accuracy, respectively. In the univariate analysis, preoperative PSA, Gleason sum, stage, margin, seminal vesicle, extra-prostatic extension (EPE), HA, HYAL1, and HA-HYAL1 were significant in predicting progression (P < 0.05). However, in the multiple logistic regression analysis, only EPE [odds ratio (OR) = 33.483; P = 0.002), HYAL1 (OR = 12.42; P = 0.009), HA-HYAL1 (OR = 18.048; P = 0.0033), and margin (OR = 26.948; P = 0.006)] were significant. Thus, in this 5-year follow-up study, HYAL1, together with EPE and margin, was found to be an independent prognostic indicator.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750291

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.

Authors:  Vinata B Lokeshwar; Luis E Lopez; Daniel Munoz; Andrew Chi; Samir P Shirodkar; Soum D Lokeshwar; Diogo O Escudero; Neetika Dhir; Norman Altman
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

2.  Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice.

Authors:  Melanie A Simpson
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

3.  Mechanotransduction in cancer.

Authors:  LiKang Chin; Yuntao Xia; Dennis E Discher; Paul A Janmey
Journal:  Curr Opin Chem Eng       Date:  2016-02-16       Impact factor: 5.163

4.  Prostate tumor cell exosomes containing hyaluronidase Hyal1 stimulate prostate stromal cell motility by engagement of FAK-mediated integrin signaling.

Authors:  Caitlin O McAtee; Christine Booth; Christian Elowsky; Lei Zhao; Jeremy Payne; Teresa Fangman; Steve Caplan; Michael D Henry; Melanie A Simpson
Journal:  Matrix Biol       Date:  2018-05-10       Impact factor: 11.583

5.  Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing.

Authors:  Alamelu G Bharadwaj; Joy L Kovar; Eileen Loughman; Christian Elowsky; Gregory G Oakley; Melanie A Simpson
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

Review 6.  Emerging roles for hyaluronidase in cancer metastasis and therapy.

Authors:  Caitlin O McAtee; Joseph J Barycki; Melanie A Simpson
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

7.  Synthesis of N-acetyl Glucosamine Analogs as Inhibitors for Hyaluronan Biosynthesis.

Authors:  Gilbert Wasonga; Yota Tatara; Ikuko Kakizaki; Xuefei Huang
Journal:  J Carbohydr Chem       Date:  2013-09-02       Impact factor: 1.667

Review 8.  Hyalurondiase: both a tumor promoter and suppressor.

Authors:  Vinata B Lokeshwar; Marie G Selzer
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

Review 9.  Role of hyaluronan in glioma invasion.

Authors:  Jong Bae Park; Hee-Jin Kwak; Seung-Hoon Lee
Journal:  Cell Adh Migr       Date:  2008-07-21       Impact factor: 3.405

10.  Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides--comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea.

Authors:  Inken Groth; Niels Grünewald; Susanne Alban
Journal:  Glycobiology       Date:  2008-12-23       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.